title: Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers.
abstract: OBJECTIVE
  A double-blind, placebo-controlled study to assess the duration of effect of lansoprazole 30 mg o.m. on intragastric pH, acid secretion, gastrin levels, the potential for rebound acidity, and the relationship between gastric acid and drug pharmacokinetic parameters.
  
  
  METHODS
  Sixteen subjects were treated with lansoprazole 30 mg daily or placebo for 14 days, followed by a 7-day post-dosing period and a post-study evaluation on day 28. Ambulatory 24-h pH was recorded and pentagastrin-stimulated acid secretion measured. Plasma kinetics of lansoprazole were determined.
  
  
  RESULTS
  Mean intragastric pH in the lansoprazole group increased significantly (P < 0.05) from baseline to day 14 compared to placebo. After cessation of treatment, secretory activity, as measured by intragastric pH, basal acid output and stimulated acid output, returned to baseline in 2 to 4 days without any overshoot, indicating the absence of acid rebound. Lansoprazole's terminal disposition half-life was 1.11 h. Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.
  
  
  CONCLUSIONS
  Lansoprazole 30 mg daily significantly increases mean intragastric pH without producing acid rebound. Regeneration of acid production depends primarily on de novo synthesis of the acid pump.
authors.affiliation: McMaster University Medical Center, Hamilton, Ontario, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Bell
authors.forename: M D
authors.initials: MD
authors.lastname: Karol
authors.forename: G
authors.initials: G
authors.lastname: Sachs
authors.forename: P
authors.initials: P
authors.lastname: Greski-Rose
authors.forename: D E
authors.initials: DE
authors.lastname: Jennings
authors.forename: R H
authors.initials: RH
authors.lastname: Hunt
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects*; D005755:Gastrins / Q000097:blood; D006801:Humans; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010418:Pentagastrin / Q000494:pharmacology; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D005755:Gastrins; D064747:Lansoprazole; D010418:Pentagastrin; D009853:Omeprazole